What is the challenge EASYGEN addresses?

Only 18% of patients have access to CAR-T therapy. About 30% of total cost-of-care are related to logistics and bridging therapy. Cell therapies often travel across borders twice under tight customs and shipping constraints. Manufacturing depends on manual, error-prone processes with cleanroom-trained technicians. Treatment costs reach over €500,000 per patient, making it unaffordable for many health systems to scale up access.

EASYGEN: Advancing CAR-T Cell Therapy for cancer in Europe

Q: What is EASYGEN's mission?

EASYGEN's goal is to enable an automated, modular manufacturing platform for CAR-T cell production at the point-of-care. The project aims to reduce treatment cost by 50%, reduce manufacturing time significantly, broaden eligibility for new European patient groups, and embed a platform seamlessly into routine hospital workflows.

Paving the way to faster, more accessible immunotherapies

EASYGEN is a collaborative EU project aiming to optimise hospital workflows of CAR-T cell therapy for a sustainable healthcare workforce.

About EASYGEN

EASYGEN Illustration of a CAR-T cell engaging with a cancer cell, representing targeted immunotherapy.

The challenge

Today's CAR-T therapies have a median vein-to-vein time of 3 to 6 weeks. Dependence on specialized, central manufacturing facilities, laborious and cost-intensive workflows, and logistics limit access to these transformative therapies.

Locke FL 2025 Blood Adv.

Only ~18%

of eligible diffuse large B-cell lymphoma (DLBCL) patients in Europe receive CAR-T therapy

IQVIA Institute 2025

`About ~30%`

of the total cost-of-care are related to logistics and bridging therapy (- by decentralization the longest and most expensive part will be removed)

Silvola S 2022 Value Health

Cross-border complexity

Cell therapies often travel across borders twice, under tight customs and shipping constraints.

Manual, error-prone processes

Manufacturing still depends on cleanroom-trained technicians and high-touch workflows which can result in delays, and errors.

Unaffordable treatment costs

With treatment costs reaching over €500,000 per patient, many health systems can’t afford to scale up access. Every day lost can mean a life lost.

Senior K 2025 Lancet

Our vision

A future where CAR-T therapies can be manufactured directly in hospitals, virus free, and worldwide — democratizing access to life-saving cell therapies and ensuring advanced treatments reach every patient who needs them.

Our mission

EASYGEN's (EASY workflow integration of GENe therapy) mission is global democratization of access to advanced cell therapies, through development of a scalable, automated, and hospital-based manufacturing solution that brings CAR-T production closer to the patient.

Reduce treatment cost by 50%

Reduce manufacturing time significantly

Broaden eligibility for new European patient groups

Embed a platform seamlessly into routine hospital workflows

More about our ambition

For any child or adult needing CAR T-cell therapy, every mile and minute matters.  The distance between patient and lab creates dangerous delays and uncertainty. By moving production into hospitals, the EASYGEN consortium will close that gap, cutting wait times and delivering life-saving therapies faster.

Tom Whitehead from the Emily Whitehead foundation

Tom Whitehead,
 co-founder of the Emily Whitehead Foundation

EASYGEN introduction video

Triangle behind a mountain range made with structural grid like texture

Latest news

A major milestone as the EASYGEN consortium kicks off

EASYGEN consortium kicks off: Decentralized, automated CAR-T manufacturing moves into the hospital.

Read article

Ring that bell

Inspired by the first CAR-T survivor, Mags McCarthy and Bruce Levine created Ring That Bell, a tribute to patients.

Read post

EASYGEN partners

EASYGEN brings together 18 international partners from academia and industry, and is led by Fresenius SE & Co.KGaA and Fraunhofer IZI as academic co-lead.

View our workpackages

Have any questions?  
Just send us a message.

We’d love to hear from you! For questions, collaborations, or more info, reach out via the form or email us at contact@easygen-consortium.eu

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

This project has received funding from the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101194710. The JU receives support from the European Union’s Horizon Europe research and innovation programme and EFPIA. — Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Branding & Website design by Belinda De Bruyn